The National Agency for Food and Drug Administration and Control (NAFDAC) has raised a public health alert over the circulation ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

Biocon Biologics collaborates with Malaysia's National Cancer Society to launch a Patient Assistance Program, providing affordable biosimilars like Trastuzumab to underserved cancer patients and ...

Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...